Pangali rega marang bathi Silence Therapeutics PLC (SLN)

Silence Therapeutics (SLN) develops cutting-edge RNA therapeutics leveraging a scalable platform that ensures low costs for mass production following certification. Its research centers are based in the UK and Germany, while substance production is distributed across Western contract manufacturing organizations. The asset's market dynamics on GURU.Markets, where the multiple stands at -23.50, confirm its status as a defensive asset independent of global economic cycles.

Silence Therapeutics focuses on developing RNA-based drugs to combat hypertension, monetizing its research through partner licensing payments. The P/E ratio reflects the market value of a single unit of the issuer's net profit. The multiplier's dynamics depend directly on price fluctuations and the efficiency of operating expense management. This indicator allows investors to assess the premium paid for the asset relative to its current ability to generate income.